| Related Articles |
High sensitivity troponins in contemporary cardiology practice: are we turning a corner?
Expert Rev Cardiovasc Ther. 2018 Jan;16(1):49-57
Authors: Mariathas M, Olechowski B, Mahmoudi M, Curzen N
Abstract
INTRODUCTION: Troponin is considered to be the gold standard biomarker for ruling out MI. There has been a drive to improve the diagnostic speed, and as such the high sensitivity cardiac troponin (hs-cTn) assays have been introduced into clinical practice and are now part of international guidelines. Their novel value in clinical practice more generally is becoming apparent. Areas covered: In this review we will evaluate the evidence for the use of hs-cTn assays in clinical practice, the issues with the assay and how the hs-cTn can be utilized in the future as a biomarker of cardiovascular risk. Expert commentary: The use of the hs-cTn assays as a 'rule out' test for MI is compelling, as a 'rule in' there are significant issues relating the specificity of the assay for MI. The future of the assay may lie in population screening and risk modeling.
PMID: 29260921 [PubMed - indexed for MEDLINE]